Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

637 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vitro assessment of the effect of clavulanic acid at concentrations achieved in human serum on the bactericidal activity of amoxicillin at physiological concentrations against Staphylococcus aureus: implications for dosage regimens.
Aguilar L, Martín M, Balcabao IP, Gómez-Lus ML, Dal-Ré R, Prieto J. Aguilar L, et al. Antimicrob Agents Chemother. 1997 Jun;41(6):1403-5. doi: 10.1128/AAC.41.6.1403. Antimicrob Agents Chemother. 1997. PMID: 9174210 Free PMC article.
Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation.
Sevillano D, Calvo A, Giménez MJ, Alou L, Aguilar L, Valero E, Carcas A, Prieto J. Sevillano D, et al. Among authors: aguilar l. J Antimicrob Chemother. 2004 Dec;54(6):1148-51. doi: 10.1093/jac/dkh463. Epub 2004 Oct 15. J Antimicrob Chemother. 2004. PMID: 15489246
Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers.
Alou L, Aguilar L, Sevillano D, Giménez MJ, Laguna B, Echeverría O, Carcas A, Lubomirov R, Casal J, Prieto J. Alou L, et al. Among authors: aguilar l. J Antimicrob Chemother. 2005 May;55(5):742-7. doi: 10.1093/jac/dki071. Epub 2005 Mar 10. J Antimicrob Chemother. 2005. PMID: 15761068 Clinical Trial.
Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.
Alou L, Aguilar L, Sevillano D, Giménez MJ, Cafini F, Valero E, Relaño MT, Prieto J. Alou L, et al. Among authors: aguilar l. J Antimicrob Chemother. 2006 Apr;57(4):714-9. doi: 10.1093/jac/dkl041. Epub 2006 Feb 21. J Antimicrob Chemother. 2006. PMID: 16492718
Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients.
Gonzalez N, Sevillano D, Alou L, Cafini F, Gimenez MJ, Gomez-Lus ML, Prieto J, Aguilar L. Gonzalez N, et al. Among authors: aguilar l. J Antimicrob Chemother. 2013 Oct;68(10):2291-5. doi: 10.1093/jac/dkt185. Epub 2013 May 14. J Antimicrob Chemother. 2013. PMID: 23674766
In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin.
Amores R, Alou L, Giménez MJ, Sevillano D, Gómez-Lus ML, Aguilar L, Prieto J. Amores R, et al. Among authors: aguilar l. Int J Antimicrob Agents. 2004 Jul;24(1):79-82. doi: 10.1016/j.ijantimicag.2004.01.016. Int J Antimicrob Agents. 2004. PMID: 15225866
637 results